Samjin Pharmaceuticals Co., Ltd.
Research Samjin Pharmaceuticals Co., Ltd. (005500.KS) on Bullrun: market cap KRW 244.80B, dividend yield 4.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker005500.KS
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyKRW
- Market capKRW 244.80B
- Dividend yield4.2%
- Financial periodQ2 2026
- RevenueKRW 79.63B
- Net incomeKRW 6.10B
- Free cash flowKRW 13.03B
- Gross margin34.6%
Valuation Snapshot
latest market cap is KRW 244.80B; dividend yield is 4.2%.
Peer valuation comparison
Latest dividend yield is 4.16% versus a Healthcare sector median of 2.4% (73.3% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 244.80B | n/a | 4.1% | 800 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 800 KRW, yield 4.2%.
About Samjin Pharmaceuticals Co., Ltd.
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome;
ETFs that hold Samjin Pharmaceuticals Co., Ltd.
US-listed ETFs
Samjin Pharmaceuticals Co., Ltd. is held by 8 US-listed ETFs, going by the latest portfolios they filed with the SEC, most traded first:
| ETF | Weight | Fee |
|---|---|---|
| Avantis Emerging Markets Equity ETF (AVEM) | <0.01% | 0.33% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
| Dimensional World ex U.S. Core Equity 2 ETF (DFAX) | <0.01% | 0.28% |
| Dimensional Emerging Markets Value ETF (DFEV) | <0.01% | 0.43% |
| State Street SPDR S&P International Small Cap ETF (GWX) | 0.02% | 0.40% |
| Dimensional Emerging Markets ex China Core Equity ETF (DEXC) | <0.01% | 0.43% |
| Dimensional Emerging Markets Sustainability Core 1 ETF (DFSE) | <0.01% | 0.41% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Samjin Pharmaceuticals Co., Ltd.'s market cap?
Samjin Pharmaceuticals Co., Ltd.'s market capitalization is KRW 244.80B.
Does Samjin Pharmaceuticals Co., Ltd. pay a dividend?
Samjin Pharmaceuticals Co., Ltd. has a dividend yield of 4.2%.
What does Samjin Pharmaceuticals Co., Ltd. do?
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases.